Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
2
40%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)

Trials by Status

terminated120%
unknown120%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_1

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

NCT04314843
completedphase_3

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

NCT04534725
completedphase_2

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

NCT04583969
unknownphase_3

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
completedphase_1

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

NCT02546284

Clinical Trials (5)

Showing 5 of 5 trials
NCT04314843Phase 1

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Terminated
NCT04534725Phase 3

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

Completed
NCT04583969Phase 2

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

Completed
NCT04351152Phase 3

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

Unknown
NCT02546284Phase 1

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5